Defective early T and T-dependent B cell activation in systemic lupus erythematosus

Lupus

Volumn 7, Issue 5, 1998, Pages 314-322

  Fernandez Gutierrez B ^a   De Miguel, S ^a   Morado, C ^a   Hernandez Garcia C ^a   Banares, A ^a   Jover, J A ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Autoimmunity; CD23; CD40L; CD69; Lymphocytes

Indexed keywords

AUTOANTIBODY; CD23 ANTIGEN; CD69 ANTIGEN; GLYCOPROTEIN GP 39; INTERLEUKIN 4; IONOMYCIN; MONOCLONAL ANTIBODY CD3; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL CULTURE; CELL INTERACTION; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

B-LYMPHOCYTES; ENZYME ACTIVATION; HUMANS; KINETICS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; PROTEIN KINASE C; RECEPTORS, IGE; T-LYMPHOCYTES;

EID: 0031847021     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120398678920226     Document Type: Article

References (46)

1. Crow MK, Friedman SM. Systemic lupus erythematosus. In: Klipple JH, Dieppe PA (eds) Rheumatology Mosby-Year Book Europe Limited: London, UK, 1994, pp 5.1-5.10
2. Bretscher P, Cohn M A theory of self-nonself discrimination. Science 1970; 169: 345-352
3. Bretscher P. The two-signal model of lymphocyte activation twenty-one years later Immunol Today 1992; 13: 74-76.
4. Steinberg AD, Klinnman DM. Pathogenesis of Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America 1988; 14: 25-41
5. Cohen PL. T- and B-cell abnormalities in systemic lupus. J Invest Dermatol 1993; 100: 69S-72S
6. Sarfati M, Delespesse G. Possible role of human lymphocyte receptor for IgE (CD23) or its soluble fragments in the in vitro synthesis of human IgE. J Immunol 1988; 141: 2195-2199.
7. Swendeman S, Thorley-Lawson DA The activation antigen BLAST-2, when shed, is an autocrine BCGF for normal and transformed B cells. EMBO J 1987; 6: 1736-1642.
8. Gordon J, Rowe M, Walker L, Guy G. Litigation of the CD23, p45 (BLAST-2, EBVCS) antigen triggers the cell-cycle progression of activated B lymphocytes. Eur J Immunol 1986; 16: 1075-1079.
9. Kintner C, Sudgen B. Identification of antigenic determinants unique to the surfaces of cells transformed by Epstein Barr virus Nature 1981; 294: 458-460.
10. Thorley-Lawson DA, Nadler LM, Bhan AK, Schooley RT. Blast-2 (EBVCS), an early cell surface marker on human B cell activation is superinduced by EBV. J Immunol 1985; 134: 3007-3012.
11. Crow MK, Jover JA, Friedman S. Direct T helper-B cell interactions induce an early B cell activation antigen. J Exp Med 1986; 164: 1760-1772.
12. De France T, Aubry JP, Rousset F, Vanbervliet B, Bonnefoy JY, Aral N, Takebe Y, Yokota T, Lee F, Arai K, DeVries J, Banchereau J. Human recombinant interleukin 4 induces Fc receptors (CD23) on normal human B lymphocytes. J Exp Med 1987; 165: 1459-1467.
13. Aubry JP, Pochon S, Graber P, Jansen KU, Bonnefoy JY CD21 is a ligand for CD23 and regulates IgE production. Nature 1992; 258: 505-507.
14. Kumagai S, Ishida H, Iwai K, Tsubata T, Umehara H, Ozaki S, Suginoshita T, Araya S, Imura H. Possible different mechanisms of B cell activation in systemic lupus erythematosus and rheumatoid arthritis, opposite expression of low-affinity receptors for IgE (CD23) on their peripheral B cells. Clin Exp Immunol 1989; 78: 348-353.
15. Chomarat P, Briolay J, Banchereau J, Miossec P Increased production of soluble CD23 in rheumatoid arthritis, and its regulation by interleukin-4 Arthritis Rheum 1993; 36: 234-242.
16. Fernández-Gutiérrez B, Hernández-García C, Bañares AA. Jover JA. CD23 hyperexpression in Rheumatoid Arthritis: Evidence for a B cell hyperresponsiveness to cognate and non-cognate T-cell signals. Clin Immunol Immunopathol 1994; 72: 321-327.
17. López-Cabrera M, Santís AG, Ferńndez-Ruiz E, Blacher R, Eash F, Sánchez-Mateos P, Śuchen-Madrid F. Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CE69, a new member of the C-type animal lectin superfamily of signal transmitting receptors J Exp Med 1993; 178: 537-547
18. Hamann J, Fiebig H, Strauss M. Expression and cloning of the early activation antigen CD69, a type II integral membrane protein with a C-type lectin domain. J Immunol 1993; 150: 4920-4927.
19. Cebrian M, Miguel Redondo J, Lopez-Rivas A, Rodriguez-Tarduch G, De Landazuri MOP, Sanchez-Madrid F. Expression and function of AIM, an activation inducer molecule of human lymphocytes, is dependent on the activation of protein kinase C. Eur J Immunol 1989; 19: 809-815.
20. Risso A, Smilovich D, Capra MC. Baldisarrol, Yan G. Bargellesi A, Cosulich ME CD69 in resting and activated T lymphocytes Its association with a GTP binding protein and biochemical requirements for its expression. J Immunol 1991; 146: 4105-4114
21. Testi R, Phillips JH, Lamer LL, Leu 23 induction as an early marker of functional CD3/T cell antigen receptor triggering. J Immunol 1989; 142: 1854-1860.
22. Verwilghen J, Vandenberghe P, Wallays G, de Boer M, Anthony N, Panayi GS, Ceuppens JL Simultaneous ligation of CD5 and CD28 on resting T lymphocytes induces T cell activation in the absence of T cell receptor/CD3 occupancy. J Immunol 1993; 150: 835-846
23. Cebrián M, Yagüe E, Rincón M, López-Botet M, Portiz de Landázun M, Sanchez-Madrid F. Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes. J Exp Med 1988; 168: 1621-1637.
24. Hara T, Jung LKL, Bjorndahl JM, Fu SM. Human T cell activation. III. Rapid induction of a phosphorilated 28kDa/32kD disulfide-linked early activation antigen (EA 1) by 12-o-tetradecanoyl phorbol-13-acetate, mitogens and antigens. J Exp Med 1986; 164: 1988-2005.
25. Fernández-Gutiérrez B, Hernández-Garcia C, Bañares AA, Jover JA. Characterization and regulation of CD69 expression on rheumatoid arthritis synovial fluid T cells. J Rheumatol 1995; 22: 413-420.
26. Hernández-García C, Fernández-Gutírrez B, Morado IC, Bañares AA, Jover JA. CD69 activation pathway in Rhematoid Arthritis synovial fluid T cells. Arthritis Rhem 1996; 39: 1277-1286.
27. Serra JA, Fernández-Gutirrez B, Hernández-Garcia C, Vidan M, Ribera JM, Bañares A, Jover JA. Early T cell activation in elderly humans Age and Ageing 1996; 25: 470-478.
28. Lederman SM, Yellin MH, Krichevsky A, Belko J, Lee JJ, Chess L. Identification of a novel surface protein on activated CD4 + T cells that induces contact dependent D cell differentiation (help). J Exp Med 1992; 175: 1901-1907.
29. Aruffo A, Farryngton M, Hollenbaugh D, Lui X, Milatovich A, Nonoyama S, Bajorath J, Grosmaire LS, Stenkamp R, Neubauer M, Roberts RL, Noelle RJ, Ledbetter JA, Francke U, Ochs HD. The CD40 ligand, gp39 is defective in activated T cells from patients with X-linked hyper Ig-M syndrome. Cell 1993; 72: 291-300.
30. Lederman S, Yellin MJ, Inghirami G, Lee JJ, Knowles DM, Chess L. Molecular interactions mediating T-B lymphocyte collaboration in human lymphoyd follicles. J Immunol 1992; 149: 3817-3826.
31. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995; 154: 1470-1480.
32. Desai-Metha A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97: 2063-2073.
33. Koshy M, Berger, D, Crow MK. Increased expression CD40 ligand on Systemic Lupus Erythematosus lymphocytes. J Clin Invest 1996; 98: 826-837.
34. Tan EM, Cohen AS, Fries IF, Masi AT, McShane DJ, Rothfield NF, Shaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus Arthritis Rheum 1982; 25: 1271-1277.
35. Hahn BH. Management of Systemic Lupus Erythematosus. In: Kelly WN, Harris Jr. ED, Ruddy S, Slegde CB (eds.) Textbook of Rheumathology. WB Saunders Company: Philadelphia, 1993, pp 1043-1056
36. Liang MH, Socher SA, Larson MG, Schur PH Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1118.
37. Gottlieb AB, Fu SM, Yu DTY, Wang CY, Halper JP, Kunkel HG. The nature of the stimulatory cell in human allogeneic and autologous MCL reactions; role of isolated IgM-bearing B cells. J Immunol. 1979; 123: 1497-1502.
38. Lane P, Traunnecker A, Hubele S, Inui S, Lanzavecchia A, Gray D. Activated human T cells express a ligand for the human B-cell associated antigen CD40 which participates in T-cell dependent activation of B lymphocytes. Eur J Immunol 1992; 22: 2573-2578.
39. Friedman SM, Jover JA, Chartash EK, Crow MK. Antigen-specific, MHC nonrestricted T helper cell-induced B cell activation. J Exp Med 1986; 164: 1773-1778.
40. Jover JA, Chartash EK, Kushner B, Friedman S, Crow MK T helper cell-induced CD23 (BLAST-2) expression: an activation marker for the high density fraction of human B cells. Clin Immunol Immunopathol 1989; 53: 99-112.
41. Crow MK, Kushner B, Jover JA, Friedman S, Mechanic SE, Stohl W. Human peripheral blood T helper cell-induced B cell activation results in B cell surface expression of the CD23 (Blast-2) antigen. Cell Immunol 1989; 121: 99-112.
42. Kuhn R, Rajewsky K, Muller W. Generation and analysis of interleukin-4 deficient mice. Science 1991; 254: 707-710.
43. Cambier JC, Pleiman CM, Clark MR. Signal transduction by the B cell antigen receptor and its coreceptors. Annu Rev Immunol 1994; 12: 457-486.
44. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nat Med 1997; 3.2: 189-195.
45. Huang YP, Perrin LH, Miescher PA, Zubler RH Correlation of T and B cell activities in vitro and serum IL-2 levels in Systemic Lupus Erythematosus. J Immunol 1986; 141: 827-833.
46. Bowen F, Haluskey J, Quill H. Altered CD40 ligand induction in tolerant T lymphocytes Eur J Immunol 1995; 25: 2830-2834.